

# TiMing of Intervention in patients with Acute Coronary Syndromes

<b>Submission date</b> 27/11/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 27/11/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/04/2019	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Shamir Mehta

**Contact details**  
Hamilton Health Sciences  
General Division  
237 Barton Street  
McMaster Clinic  
Room 508  
Hamilton, Ontario  
Canada  
L8L 2X2

**Type(s)**  
Public

**Contact name**  
Ms Brandi Meeks

**Contact details**  
Population Health Research Institute (PHRI)  
McMaster University/Hamilton Health Sciences  
237 Barton St E  
Hamilton

Canada  
ON L8L 2X2  
+1 (0)905 527 4322 ext. 44818  
brandi@cardio.on.ca

## **Additional identifiers**

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**  
NCT00552513

**Secondary identifying numbers**  
MCT-79654

## **Study information**

### **Scientific Title**

An International randomised trial of early versus delayed invasive strategies in patients with non-ST segment elevation acute coronary syndromes

### **Acronym**

TIMACS

### **Study objectives**

1. In patients with acute coronary syndromes (ACS), a strategy of routine early coronary angiography (less than 24 hours after randomisation) and intervention is superior to a strategy of delayed coronary angiography (more than 36 hours after randomisation) and intervention in preventing major cardiovascular events
2. In patients with ACS, a delayed invasive strategy will result in lower rates of major bleeding versus a strategy of early angiography and revascularisation
3. A strategy of early coronary angiography and revascularisation will be more cost effective than a strategy of delayed coronary angiography and revascularisation

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

1. Research Ethics Board of the Hamilton Health Sciences/McMaster Health Sciences, Hamilton, Ontario, Canada, 26/05/2005
2. Comit  de  tica em Pesquisa, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil, 29/05/2006
3. Comit  d'Ethique M dicale, Centre Hospitauer Regional De Huy, De Huy, Belgium, 12/10/2005
4. Ethics Committee of the Middle Slovak Institute of Cardiovascular Diseases, Banska Bistrica, Slovakia, 26/10/2006
5. University Clinical Emergency Hospital Mures Clinic of Cardiology, Targu Mures, Romania, 01/11/2006

### **Study design**

Therapeutic management strategy and procedures intervention type randomised parallel two-armed multicentre multi-national trial with assessor blinding

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Acute coronary syndromes (unstable angina and non-ST segment elevation myocardial infarction)

### **Interventions**

Early intervention:

Coronary angiography and intervention as soon as possible (within 24 hours of randomisation).

Delayed intervention:

Coronary angiography and intervention any time after 36 hours after randomisation.

### **Intervention Type**

Procedure/Surgery

### **Primary outcome measure**

The first occurrence of the composite death/myocardial (re-)infarction/stroke up to day 180.

### **Secondary outcome measures**

1. The composite of death, myocardial (re-)infarction, stroke, refractory ischaemia or repeat revascularisation at 180 days
2. The first occurrence of any component of the composite of death myocardial infarction and refractory ischaemia until day 14, 30, 90 and at six months (day 180)
3. Stroke at 30 days and 180 days
4. Need for mechanical or pharmacological coronary revascularisation (i.e., percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG], thrombolysis) at days 30, 90 and 180 days

### **Overall study start date**

15/06/2005

### **Completion date**

01/05/2008

# Eligibility

## Key inclusion criteria

1. Patients presenting or admitted to hospital with symptoms suspected to represent an acute coronary syndrome (unstable angina or MI without persistent ST elevation), i.e. clinical history consistent with new onset, or a worsening pattern, of characteristic ischaemic chest pain or ischaemic symptoms occurring at rest or with minimal activity (lasting longer than five minutes or requiring sublingual nitroglycerin for relief of the pain)
2. Able to randomise within 24 hours of the onset of the most recent episode of symptoms
3. At least two of the three following additional criteria:
  - 3.1. Age more than or equal to 60 years, either sex
  - 3.2. Troponin T or I or creatine kinase - myocardial bands (CK-MB) above the upper limit of normal for the local institution
  - 3.3. Electrocardiogram (ECG) changes compatible with ischaemia (i.e., ST depression at least 1 mm in two contiguous leads or T wave inversion more than 3 mm or any dynamic ST shift or transient ST elevation)
4. Written informed consent dated and signed

## Participant type(s)

Patient

## Age group

Adult

## Sex

Both

## Target number of participants

4000

## Key exclusion criteria

1. Age less than 21 years
2. Not a suitable candidate for revascularisation
3. Co-morbid condition with life expectancy less than six months

## Date of first enrolment

15/06/2005

## Date of final enrolment

01/05/2008

# Locations

## Countries of recruitment

Argentina

Belgium

Brazil

Bulgaria  
Canada  
Chile  
China  
Czech Republic  
France  
Germany  
Greece  
India  
Poland  
Romania  
Slovakia  
Slovenia  
Switzerland  
United States of America

**Study participating centre**  
**Hamilton Health Sciences**  
Hamilton, Ontario  
Canada  
L8L 2X2

## **Sponsor information**

**Organisation**  
Population Health Research Institute (PHRI) (Canada)

**Sponsor details**  
McMaster University/Hamilton Health Sciences  
237 Barton St East  
Hamilton, Ontario  
Canada  
L8L 2X2

+1 (0)905 527 4322 ext. 44555  
crackbe@phri.ca

**Sponsor type**

Research organisation

**Website**

<http://www.phri.ca>

**ROR**

<https://ror.org/03kwaeq96>

## **Funder(s)**

**Funder type**

Research organisation

**Funder Name**

Canadian Institutes of Health Research

**Alternative Name(s)**

Instituts de Recherche en Santé du Canada, Canadian Institutes of Health Research (CIHR), CIHR\_IRSC, Canadian Institutes of Health Research | Ottawa ON, CIHR, IRSC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Canada

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>	results	21/05/2009	10/04/2019	No	No
<a href="#">Results article</a>				Yes	No